EUVIMEDEUVIMED entdecken
Crossref

Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura

Tim Postmus, Nuno A G Graça, Juliana Ferreira de Santana, Bogac Ercig, Pieter Langerhorst, Brenda Luken, Bérangère S Joly, Karen Vanhoorelbeke, Agnès Veyradier, Paul Coppo, Jan Voorberg

Journal of Thrombosis and Haemostasis · 2023

DOI: 10.1016/j.jtha.2023.08.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Tim Postmus und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Hematology, Sanquin-Academic Medical Center Landsteiner Laboratory, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Thrombosis, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: LSBR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic disorder, with 1.5 to 6.0 cases per million per year. The majority of patients with TTP develop inhibitory autoantibodies that predominantly target the spacer domain of ADAMTS-13. ADAMTS-13 is responsible for cleaving von Willebrand factor (VWF) multimers, thereby regulating platelet adhesion at sites of high-vascular shear stress. Inhibition and/or clearance of ADAMTS-13 by pathogenic autoantibodies results in accumulation of VWF multimers that promotes the formation of platelet-rich microthrombi. Previously, we have shown that insertion of a single N-glycan (NGLY) in the spacer domain prevents the binding of antispacer domain antibodies. OBJECTIVES: To explore whether NGLY mediated shielding of the ADAMTS-13 spacer domain effectively prevents binding of pathogenic antispacer autoantibodies in patients with immune-mediated TTP (iTTP). METHODS: We screened 5 NGLY-ADAMTS-13 variants (NGLY3, NGLY7, NGLY8, NGLY3+7, and NGLY3+8) for binding of autoantibodies and for their activity in the presence and absence of 50 samples derived from patients with iTTP. RESULTS: NGLY variants showed greatly reduced antibody binding, down to 27% of wild-type (wt) ADAMTS-13 binding. Moreover, NGLY variants of ADAMTS-13 remained more active in FRETS-VWF73 assay in the presence of the plasma samples from these 50 patients with acute phase iTTP when compared with wtADAMTS-13. On average, wtADAMTS-13 activity was reduced to 37% of regular levels in the presence of plasma, while NGLY3 and NGLY3+7 remained 69% and 81% active, respectively. CONCLUSION: These results reinforce our previous findings that NGLYs shield ADAMTS-13 from antibody binding and hence restore ADAMTS-13 activity in the presence of autoantibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicThrombosisPurpura, Thrombocytopenic, IdiopathicHumansADAMTS13 Proteinvon Willebrand FactorBlood PlateletsAutoantibodies

Stichwörter der Autor:innen

ADAMTS-13autoantibodieshemostasisthrombotic microangiopathiesthrombotic thrombocytopenic purpura

Substanzen

ADAMTS13 Proteinvon Willebrand FactorAutoantibodies

Autor:innen und Institutionen

  • Department of Molecular Hematology, Sanquin-Academic Medical Center Landsteiner Laboratory, Amsterdam, The Netherlands.
  • Division of Biochemistry and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sanquinnovate, Amsterdam, The Netherlands.
  • Centre National de Référence des Microangiopathies Thrombotiques, hôpital Saint-Antoine, AP-HP. Sorbonne Université, Paris, France; Service d'hématologie biologique, hôpital Lariboisière et EA3518 Institut de Recherche…
  • Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.
  • Department of Molecular Hematology, Sanquin-Academic Medical Center Landsteiner Laboratory, Amsterdam, The Netherlands; Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands. Electronic…

Förderung

  • LSBR

Zitieren

APA

Postmus, T., Graça, N. A. G., Ferreira de Santana, J., Ercig, B., Langerhorst, P., Luken, B., Joly, B. S., Vanhoorelbeke, K., Veyradier, A., Coppo, P., & Voorberg, J. (2023). Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.08.017

Vancouver

Postmus T, Graça NAG, Ferreira de Santana J, Ercig B, Langerhorst P, Luken B, et al. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.08.017

BibTeX
@article{Postmus2023,
  author = {Postmus, Tim and Graça, Nuno A G and Ferreira de Santana, Juliana and Ercig, Bogac and Langerhorst, Pieter and Luken, Brenda and Joly, Bérangère S and Vanhoorelbeke, Karen and Veyradier, Agnès and Coppo, Paul and Voorberg, Jan},
  title = {Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  doi = {10.1016/j.jtha.2023.08.017}
}
Kostenlos starten →